• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Psychiatry

Xanomeline-trospium treatment showed improvement in patients with schizophrenia

byRicha SharmaandHarsh Shah
February 27, 2021
in Psychiatry
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Xanomeline-trospium treatment showed a greater reduction in the degree of psychosis in patients with schizophrenia compared to placebo.

2. Patients treated with xanomeline-trospium experienced adverse events such as constipation and nausea but no increase in the incidence of extrapyramidal symptoms.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Current medications, primarily dopamine-antagonists, are used to treat schizophrenia. These medications cause side effects including metabolic disturbances leading to patients withdrawing from prescribed dosing. However, little is known about muscarinic cholinergic receptor agonists and peripheral antagonists as treatments for schizophrenia. As such, the trial examined the safety and efficacy of a combination treatment of xanomeline, a muscarinic receptor agonist, and trospium, a peripherally restricted muscarinic receptor antagonist. Patients receiving the treatment displayed a lower positive and negative syndrome scale (PANSS) score at the end of the study, which indicated this treatment is effective in patients with poor functional status. However, the study resulted in adverse events which were common in both study groups. The study was limited by a small number of study participants resulting in a low power value. Moreover, the study was conducted over a short period of time with no long-term follow-up. Nonetheless, this study’s results are significant, and its findings highlight the xanomeline-trospium combination treatment to be effective in patients with schizophrenia.

Click to read the study in NEJM

Relevant Reading: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multiepisode schizophrenia: a systematic review and network meta-analysis

In-Depth [randomized controlled trial]: This phase 2, double-blind study enrolled 182 participants across 12 hospitals in the United States. Participants between 18 and 60 years of age diagnosed with schizophrenia, a PANSS baseline score of 80 or more, and an episode of acute exacerbation or relapse of psychosis were enrolled into the study. Participants with a history of treatment resistance to antipsychotic medications were excluded from the study. Patients were randomized in a 1:1 ratio to xanomeline-trospium or placebo, respectively. The primary endpoint of the study was a change in the PANSS score from baseline at week five. The study results displayed a mean change of -17.4 points in the treatment group and -5.9 points in the placebo group (least-square means difference, -11.6 points; 95% confidence interval [CI], -16.1 to -7.1; P<0.001). Common adverse events included constipation, nausea, xerostomia, dyspepsia, and vomiting (treatment group, 54%; placebo group, 43%). Overall, the study showed a xanomeline-trospium combination treatment for schizophrenia shows was efficacious; however, further investigation needs to be conducted for the safety of the treatment.

RELATED REPORTS

Emraclidine is safe and well-tolerated for the treatment of schizophrenia

Wellness Check: Spirituality

Excitatory noninvasive brain stimulation interventions improved negative symptoms in schizophrenia

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: muscarinic cholinergic receptor agonistperipheral antagonistPsychosisschizophreniaxanomeline-trospium
Previous Post

Idecabtagene vicleucel showed a response in pre-treated multiple myeloma

Next Post

Relugolix combination therapy led to reduction in uterine fibroid symptoms

RelatedReports

Majority of pediatric medication-related visits to emergency department are preventable
Chronic Disease

Emraclidine is safe and well-tolerated for the treatment of schizophrenia

December 28, 2022
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
Wellness

Wellness Check: Spirituality

December 1, 2022
“No Evidence of Disease Activity” may be useful goal in multiple sclerosis
Psychiatry

Excitatory noninvasive brain stimulation interventions improved negative symptoms in schizophrenia

September 7, 2022
Majority of pediatric medication-related visits to emergency department are preventable
Psychiatry

Variation in antipsychotic medication responsiveness present amongst schizophrenia patients

September 2, 2022
Next Post
Simvastatin associated with slowed fibroid growth in mice

Relugolix combination therapy led to reduction in uterine fibroid symptoms

Colchicine may lower the risk of cardiovascular events in patients with coronary disease

2 Minute Medicine Rewind March 1, 2021

Adolescent mothers in protective care more likely to have their children placed in care

COVID-19 lockdowns associated with increased quiet time and less spoken communication for children with cochlear implants

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Factors associated with breastfeeding rates in Canada
  • Efanesoctocog alfa is efficacious in treating severe hemophilia A
  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options